This product is an aromatic propionic acid derivative and a non-steroidal anti-inflammatory analgesic. In addition to inhibiting cyclooxygenase, this product also has a certain effect of inhibiting lipoxygenase and reducing bradykinin, thereby reducing the pain sensation at the site of inflammation and injury. Because bradykinin and prostaglandins can cause pain together. Bradykinin can also cause uterine contraction, so this product is used for dysmenorrhea, mainly by inhibiting bradykinin, thereby inhibiting uterine contraction and analgesia to achieve therapeutic effects. This product also has a certain central analgesic effect.

This product is an aromatic propionic acid derivative and a non-steroidal anti-inflammatory analgesic. In addition to inhibiting cyclooxygenase, this product also has a certain effect of inhibiting lipoxygenase and reducing bradykinin, thereby reducing the pain sensation at the site of inflammation and injury. Because bradykinin and prostaglandins can cause pain together. Bradykinin can also cause uterine contraction, so this product is used for dysmenorrhea, mainly by inhibiting bradykinin, thereby inhibiting uterine contraction and analgesia to achieve therapeutic effects. This product also has a certain central analgesic effect.

Maintains normal blood and extracellular fluid volume and osmotic pressure in the human body; plays a decisive role in osmotic pressure

Supplement potassium ions to maintain the stability of body fluid volume and osmotic pressure

Supplement calcium ions to maintain the stability of body fluid volume and osmotic pressure

This product is a methylhydroxyglutaryl coenzyme A (HMG-COA) reductase inhibitor, which inhibits the synthesis of endogenous cholesterol and is a blood lipid regulator. Literature data show that it can reduce the cholesterol (TC) content in the serum, liver, and aorta of hyperlipidemia rabbits, and reduce the levels of very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C).

This product is a methylhydroxyglutaryl coenzyme A (HMG-COA) reductase inhibitor, which inhibits the synthesis of endogenous cholesterol and is a blood lipid regulator. It has the effect of reducing the cholesterol (TC) content in the serum, liver, and aorta of hyperlipidemia rabbits, and reducing the levels of very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C).